Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Astera Labs, Inc.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-97.7% vs price
Base Case (Median)
-94.4% vs price
Bull Case (75th pct.)
-89.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $4.24 | -98.5% | High (40%) |
| PE Comparable | $51.23 | -82.4% | Medium (25%) |
| Graham Number | $18.96 | -93.5% | Low (10%) |
| EV/EBITDA | $13.84 | -95.2% | Medium (20%) |
| EV/FCF | $32.89 | -88.7% | Medium (20%) |
| Earnings Power Value | $0.99 | -99.7% | Medium (50%) |
Based on 6 out of 7 methods, ALAB appears overvalued at the current price of $290.80. The base case fair value of $16.40 implies 94.4% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.